Apcin-A

Target: This ligand targets CDC20, an activator of the anaphase-promoting complex/cyclosome in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for CDC20, an activator of the anaphase-promoting complex/cyclosome. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings CDC20 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Apcin Degradation: Apcin-A can be used as a ligand component to design PROTACs that recruit E3 ligases and drive selective ubiquitination of Apcin. In targeted protein degradation studies, this enables systematic evaluation of degradation efficiency, residence-time effects, and the relationship between binding affinity and functional protein loss.

• E3 Ligase Recruitment Optimization: Incorporate Apcin-A into PROTAC architectures with different E3 ligase-binding modules to map how ligase choice and linker chemistry influence Apcin ubiquitination. Researchers can compare degradation kinetics, ubiquitin chain formation, and dose–response behavior to identify PROTAC configurations that maximize degradation while minimizing off-target effects.

• Linker and Geometry Tuning: Use Apcin-A to explore PROTAC structure–activity relationships by varying linker length, flexibility, and attachment points. These studies can reveal how spatial proximity between the Apcin ligand and recruited E3 ligase affects ternary complex stability, thereby controlling degradation potency and selectivity in cellular protein turnover assays.

• Mechanistic Studies of Ubiquitination: Apcin-A–based PROTACs support mechanistic investigations of Apcin degradation pathways, including dependence on proteasome activity and E3 ligase engagement. By combining degradation readouts with ubiquitination assays and ternary complex measurements, researchers can dissect whether observed loss of Apcin arises from productive ubiquitination and efficient trafficking to the proteasome.

Apcin-A is a APC/C regulator ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Apcin-A is characterized by primary or secondary amine/basic nitrogen centers; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.